Author Affiliations: Children's Hospital Los Angeles, California (Drs Ward and Kapoor); University of Southern California, Keck School of Medicine, Los Angeles (Dr Kapoor); Rush University College of Nursing, Chicago, Illinois (Drs Ward, Fogg, Breitenstein, and Swanson); and Duke University School of Nursing, Durham, North Carolina (Dr Rodgers).
Cancer Nurs. 2019 Nov/Dec;42(6):448-457. doi: 10.1097/NCC.0000000000000652.
Parents of children undergoing hematopoietic stem cell transplantation (HSCT) are at risk of adverse health outcomes due to their intense caregiver demands.
The aim of this study was to describe adverse health outcomes in parents of children who survived an allogeneic HSCT done within the past 1 to 10 years.
This cross-sectional study, conducted at a children's hospital in the western United States, enrolled English- and Spanish-speaking parents of children who survived allogeneic HSCT between 2005 and 2015. Outcome measures included Beck Anxiety and Depression Inventories, Perceived Stress and Parent Stress Scales, Physical Symptom Inventory, and Short-Form 36 version 2. Parent scores were compared with normative means. Subsequently, the parent sample was stratified by the amount of time since their child's HSCT for comparison between groups.
Fifty-four mothers and 7 fathers (n = 61) were enrolled. Global mental health scores were lower for parents in the sample compared with norms (P = .003). Parents in the sample reported moderate anxiety and depression (20% and 23%, respectively), yet reported less parenting stress and superior health outcomes compared with norms (P < .001). Social functioning and general health scores were lower for parents whose children survived an allogeneic HSCT done within the past 1 to 4.99 years (P = .012).
Parents of survivors of allogeneic HSCT may concurrently experience posttraumatic growth and stress following their child's HSCT.
Health screening and psychological support for parents of children post-HSCT may help to identify parents at risk of adverse outcomes and allow for early, targeted interventions.
由于高强度的照护需求，接受造血干细胞移植（HSCT）的患儿的父母面临不良健康结局的风险。
本研究旨在描述过去 1 至 10 年内接受异基因 HSCT 治疗的存活患儿的父母的不良健康结局。
这是一项在美国西部一家儿童医院进行的横断面研究，纳入了过去 5 年（2005 年至 2015 年）接受异基因 HSCT 治疗的存活患儿的英语和西班牙语家长。结局指标包括贝克焦虑和抑郁量表、感知压力和父母压力量表、身体症状量表和简明健康状况量表 36 版 2 型。将家长评分与常模进行比较。随后，根据患儿 HSCT 后时间的长短对家长样本进行分层，以比较组间差异。
共纳入 54 名母亲和 7 名父亲（n = 61）。与常模相比，样本中的父母整体心理健康评分较低（P =.003）。样本中的父母报告有中度焦虑和抑郁（分别为 20%和 23%），但报告的育儿压力和健康结局均优于常模（P <.001）。过去 1 至 4.99 年内接受异基因 HSCT 治疗的患儿的父母，其社会功能和一般健康评分较低（P =.012）。
异基因 HSCT 后存活患儿的父母可能同时经历创伤后成长和压力。
对接受 HSCT 后的儿童的父母进行健康筛查和心理支持可能有助于识别有不良结局风险的父母，并允许早期、有针对性的干预。
